Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Big Pharma Holds Steady With One-Third Of Novel Agents Approved In US In 2020

Executive Summary

Gilead and Roche ended the year involved in three novel agents apiece, thanks to a combination of internal research and external licensing. 

You may also be interested in...



Quick Listen: Scrip’s Five Must-Know Things

Join us for an audio catch-up on the major events in the global biopharma industry over the past business week, as reported by Scrip's worldwide team, in this podcast version of Five Must-Know Things. 

Aducanumab Approval Decision Delayed: Could This Be Good News?

Even analysts who still doubt the FDA will approve the anti-amyloid antibody as the first disease-modifying Alzheimer’s treatment said aducanumab’s likelihood of approval has improved.

Is Bristol’s Long-Term Revenue Growth A Potential Salve For Celgene Shareholders?

CEO Caforio used the J.P. Morgan stage to try to assuage Celgene investors who recently lost out on a $9 CVR under the buyout, playing up the long-term promise of the combined company. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143774

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel